CA2972995A1 - Methodes de traitement de maladies inflammatoires - Google Patents

Methodes de traitement de maladies inflammatoires Download PDF

Info

Publication number
CA2972995A1
CA2972995A1 CA2972995A CA2972995A CA2972995A1 CA 2972995 A1 CA2972995 A1 CA 2972995A1 CA 2972995 A CA2972995 A CA 2972995A CA 2972995 A CA2972995 A CA 2972995A CA 2972995 A1 CA2972995 A1 CA 2972995A1
Authority
CA
Canada
Prior art keywords
antibody
weeks
administered
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2972995A
Other languages
English (en)
Other versions
CA2972995C (fr
Inventor
Matthias Arndt
Stella ASLANYAN
Mary Ruth FLACK
Annette Bettina GALLER
Bojan LALOVIC
Steven John PADULA
Paul Russell SCHOLL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2972995A1 publication Critical patent/CA2972995A1/fr
Application granted granted Critical
Publication of CA2972995C publication Critical patent/CA2972995C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne de manière générale des méthodes de traitement de maladies liées à l'IL-23, en particulier des maladies inflammatoires, telles que le psoriasis, l'arthrite psoriasique ou la spondylarthrite axiale (spinale)(ax-SpA), comprenant la spondylarthrite ankylosante et l'ax-SpA non radiographique, à l'aide d'anticorps anti-IL-23A.
CA2972995A 2015-02-04 2016-02-02 Methodes de traitement de maladies inflammatoires Active CA2972995C (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201562111731P 2015-02-04 2015-02-04
US62/111,731 2015-02-04
US201562130876P 2015-03-10 2015-03-10
US62/130,876 2015-03-10
US201562135335P 2015-03-19 2015-03-19
US62/135,335 2015-03-19
US201562145764P 2015-04-10 2015-04-10
US62/145,764 2015-04-10
US201562204520P 2015-08-13 2015-08-13
US62/204,520 2015-08-13
US201562235631P 2015-10-01 2015-10-01
US62/235,631 2015-10-01
PCT/US2016/016061 WO2016126638A1 (fr) 2015-02-04 2016-02-02 Méthodes de traitement de maladies inflammatoires

Publications (2)

Publication Number Publication Date
CA2972995A1 true CA2972995A1 (fr) 2016-08-11
CA2972995C CA2972995C (fr) 2025-09-16

Family

ID=

Also Published As

Publication number Publication date
JP2020125338A (ja) 2020-08-20
KR20170120616A (ko) 2017-10-31
NZ733136A (en) 2024-04-26
JP7042298B2 (ja) 2022-03-25
JP7044824B2 (ja) 2022-03-30
JP2025060797A (ja) 2025-04-10
MX2022006573A (es) 2022-07-11
JP6758304B2 (ja) 2020-09-23
EA201791734A1 (ru) 2018-01-31
US20160222102A1 (en) 2016-08-04
AU2025204286A1 (en) 2025-07-03
IL253118A0 (en) 2017-08-31
WO2016126638A1 (fr) 2016-08-11
IL323562A (en) 2025-11-01
AU2016215535B2 (en) 2021-09-16
SG11201705728RA (en) 2017-08-30
AU2021286378B2 (en) 2025-03-13
PH12017501378A1 (en) 2018-01-08
JP2018505882A (ja) 2018-03-01
MX2017010037A (es) 2018-05-15
CN113559258A (zh) 2021-10-29
BR112017014684A2 (en) 2018-01-09
MX392789B (es) 2025-03-21
AU2016215535A1 (en) 2017-07-13
IL321788A (en) 2025-08-01
JP2025060798A (ja) 2025-04-10
EP3253794A1 (fr) 2017-12-13
JP7042297B2 (ja) 2022-03-25
AU2021286378A1 (en) 2022-01-20
JP2020125339A (ja) 2020-08-20
JP2022081644A (ja) 2022-05-31
IL307578A (en) 2023-12-01
KR20240158362A (ko) 2024-11-04
SG10202103879YA (en) 2021-05-28
US12441785B2 (en) 2025-10-14
CL2017001960A1 (es) 2018-04-20
MX2022006575A (es) 2022-07-11
US20260035453A1 (en) 2026-02-05
CN107206081A (zh) 2017-09-26
EP4670787A2 (fr) 2025-12-31
JP2020125340A (ja) 2020-08-20

Similar Documents

Publication Publication Date Title
AU2021286378B2 (en) Methods of treating inflammatory diseases
JP2026048776A (ja) 炎症性疾患の処置法
US20250304674A1 (en) Methods of treating inflammatory diseases
CA2972995C (fr) Methodes de traitement de maladies inflammatoires
EA046375B1 (ru) Способ лечения воспалительных заболеваний

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210120

EEER Examination request

Effective date: 20210120

EEER Examination request

Effective date: 20210120

EEER Examination request

Effective date: 20210120

EEER Examination request

Effective date: 20210120

EEER Examination request

Effective date: 20210120

EEER Examination request

Effective date: 20210120

EEER Examination request

Effective date: 20210120

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20240917

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250130

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250130

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250130

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250605

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250605